non-dilutive funding 2021

[eBook] Non-dilutive Funding Sources for Advanced Therapy Biotechs 2021

A guide to the non-dilutive funding applications that are open or opening soon from the US and Europe.
Cell and gene therapy is a hot investment. A shattering $19.9 billion was raised in 2020, significantly exceeding previous annual financing records and over $10 billion higher than 2019.
 
And the data at this year’s ASCO proved why.
 
The contribution of academic and early-stage biotech to the innovation and success of the industry is skyrocketing, but huge capital investments and IPOs aren’t generally accessible for these smaller companies. How can they access non-dilutive funding that allows them to focus on scientific innovation rather than financial milestones and investor pressure?
 
Non-dilutive funding sources allow you to retain value and control of your company or product while maturing and gaining experience to become a more attractive prospect when the time for dilutive levels of funding arises.
 
There can be some downsides, grants can be restrictive in terms of their geography and eligibility criteria, as well as being time sensitive.
 
This eBook presents thirteen non-dilutive funding applications that are open or opening soon from USA and Europe.